493
Downloads
12
Episodes
This is the monthly podcast of ACCRU, designed to tell the stories behind the innovative research of our members. Our mission is to establish the next level study for cancer research across the major disease groups. We promise our members the resources and collaboration to conduct innovative trials that transform patient care.ACCRU stands for ”Academic and Community Cancer Research United.”
Episodes
Friday Mar 24, 2023
Friday Mar 24, 2023
Outcomes in cancer treatment depend on the most basic question: Did the patient take the drug? In a recent National Cancer Database analysis of breast cancer patients with hormone receptor breast cancer who had received neoadjuvant chemotherapy, Dr. Matthew Goetz, and his team discovered that upwards of 40% of patients never started endocrine therapy. Those who didn't take their adjuvant endocrine therapy had a 60 to 70% higher risk of death. In this episode with Dr. Goetz, who directs the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) and co-leads the Women's Cancer Program at the Mayo Clinic Comprehensive Cancer Center, he also discusses an innovative ACCRU neoadjuvant endocrine trial for premenopausal women with hormone receptor positive, HER2 negative breast cancer that recently activated. Podcast host Dr. Kristen Ciombor and Dr. Goetz also highlight the importance of community physicians in trial development and patient outcomes.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.